ANKK1

Across TCGA pan-cancer cohorts, ANKK1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKK1 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ANKK1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKK1 expression acts as an unfavorable survival marker.

BRCA, HNSC, and ESCA are the cancer types where ANKK1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.064	0.924	<.001	48	view →
HNSC	OS	Median	All	0.002	0.768	<.001	30	view →
ESCA	DFS	Median	II,III,IV	0.162	0.525	.011	18	view →
LIHC	OS	Median	All	0.098	0.777	<.001	12	view →
KIRC	DFS	Median	All	0.127	0.865	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKK1–BRCA (OS)

Open the BRCA breakdown →